Summary
Like idiopathic Parkinson’s disease (iPD), Progressive Supra-nuclear Palsy (PSP) is characterized, inter alia, by a pronounced non-overlapping loss of dopamine (DA) in caudate, putamen and substantia nigra.
Unlike iPD, in PSP the striatal DA loss is more severe in the caudate than in the putamen; this may contribute to the higher frequency of cognitive deficits in PSP.
In contrast to iPD, in patients with PSP the serotonin (5-HT) levels in the basal ganglia are not significantly reduced, thus resulting in a relative predominance of the inhibitory serotonergic influences on the motor behaviour in these patients.
It is suggested that combination of levodopa with a 5-HT receptor blocker may substantially improve the (poor) responsiveness of patients with PSP to DA substitution therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andén N-E, Grabowska M (1976) Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Eur J Pharmacol 39: 275–282.
Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental Parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436–1438.
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Scitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455.
Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) [3H]Spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 99: 167–175.
Borison RL, Pathiraja AP, Diamond BI (1992) Influence of serotonin on dopamin-ergically mediated extrapyramidal side-effects. Mov Disord [Suppl] 7: 55.
Brusa A, Mancardi GL, Bugiani O (1980) Progressive supranuclear palsy 1979: an overview. Ital J Neurol Sci 4: 205–222.
DeLong MR, Georgopoulos AP, Crutcher MD (1983) Cortico-basal ganglia relations and coding of motor performance. Exp Brain Res [Suppl] 7: 29–40.
Divac I, Öberg RGE (1979) Current conceptions of neostriatal functions: history and an evaluation. In: Divac I, Öberg RGE (eds) The neostriatum. Pergamon Press, Oxford, pp 215–230.
Divac I, Rosvold HE, Szwarcbart MK (1967) Behavioural effects of selective ablation of the caudate nucleus. J Comp Physiol Psychol 63: 184–190.
Donaldson IMacG, Dolphin AC, Jenner P, Pycock C, Marsden CD (1978) Rotational behaviour produced in rats by ipsilateral electrolytic lesions of the ascending nor-adrenergic bundles. Brain Res 138: 487–509.
Dray A (1981) Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. J Physiol (Paris) 77: 393–403.
Evarts EV, Kimura M, Wurtz RH, Hikosaka O (1984) Behavioural correlates of activity in basal ganglia neurons. Trends Neurosci 7: 447–453.
Gibb WRG (1991) Neuropathology of the substantia nigra. Eur Neurol [Suppl 1] 31: 48–59.
Grenhoff J, Svensson TH (1989) Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur J Pharmacol 165: 11–18.
Hassler R (1938) Zur Pathologie der Paralysis Agitans und des post-enzephalitischen Parkinsonismus. J Psychol Neurol 48: 387–476.
Hornykiewicz O (1976) Neurohumoral interactions and basal ganglia function and dysfunction. In: Yahr MD (ed) The basal ganglia. Raven Press, New York, pp 269–278.
Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson’s disease. Adv Neurol 45: 19–34.
Hornykiewicz O, Kish SJ, Rajput AH (1990) Neurochemical aspects of Parkinson’s disease and the dementing brain disorders: relation to brain ageing. In: Nagatsu T, Fisher A, Yoshida M (eds) Basic, clinical, and therapeutic aspects of Alzheimer’s and Parkinson’s disease, vol 1. Plenum Press, New York, pp 445–452.
Jackson JA, Jankovic J, Ford J (1983) Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 13: 273–278.
Jansen Steur ENH (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43: 211–213.
Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18: 530–536.
Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. N Engl J Med 318: 876–880.
Korsgaard S, Gerlach J, Christensson E (1985) Behavioural aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118: 245–252.
Lategan AJ, Marien MR, Colpaert FC (1990) Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res 523: 134–138.
Lloyd KG (1977) Neurotransmitter interactions related to central dopamine neurons. In: Youdim MBH, Lovenberg W, Sharman DE, Lagnado TR (eds) Essays in neurochemistry and neuropharmacology. Wiley, Chichester, pp 131–207.
Maertens de Noordhout A, Delwaide PJ (1986) Open pilot trial of ritanserin in Parkinsonism. Clin Neuropharmacol 9: 480–484.
Meco G, Marini S, Lestingi L, Modarelli F, Agnoli A (1986) Efficacy of ritanserin on tremor and abnormal involuntary movements in Parkinson’s disease. Abstract, 15th C.I.N.P. Congress, San Juan, Puerto Rico, p 298.
Mogenson GJ, Yim CY (1981) Electrophysiological and neuropharmacological-behavioural studies of the nucleus accumbens: implications for its role as a limbicmotor interface. In: Chronister RB, Defrance JF (eds) The neurobiology of the nucleus accumbens. Haer Institute for Electrophysiological Research, Brunswick, ME, pp 210–229.
Moore RY, Bloom FE (1978) Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Ann Rev Neurosci 1: 129–169.
Narabayashi H (1993) Three types of akinesia in the progressive course of Parkinson’s disease. Adv Neurol 60: 18–24.
Nyberg P, Nordberg A, Wester P, Winblad B (1983) Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson’s disease. Neurochem Pathol 1: 193–202.
Owen AM, Beksinska M, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Sahakian BJ, Robbins TW (1993) Visuo-spatial memory deficits at different stages of Parkinson’s disease. Neuropsychologia (in press).
Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, LHeureux R, Hauw JJ, Duyckaerts C, Gray F, Morel-Maroger A, Rascol A, Serdaru M, Agid Y (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18: 523–529.
Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. Arch Neurol 10: 333–359.
Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psycho-pharmacology 98: 45–50.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Wien
About this paper
Cite this paper
Hornykiewicz, O., Shannak, K. (1994). Brain monoamines in progressive supranuclear palsy — comparison with idiopathic Parkinson’s disease. In: Tolosa, E., Duvoisin, R., Cruz-Sánchez, F.F. (eds) Progressive Supranuclear Palsy: Diagnosis, Pathology, and Therapy. Journal of Neural Transmission. Supplementa, vol 42. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6641-3_17
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6641-3_17
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82541-9
Online ISBN: 978-3-7091-6641-3
eBook Packages: Springer Book Archive